Newron reviews FDA clinical hold feedback for ENIGMA-TRS
Newron said it received an anticipated FDA written communication placing ENIGMA-TRS on clinical hold at U.S. study centers and is reviewing feedback while preparing a response. The company expects ENIGMA-TRS 1 enrollment completion by mid-October and topline 12-week data in Q1.